Guided molecular missiles for tumor-targeting chemotherapy - Case studies using the second-generation taxoids as warheads

Accounts of Chemical Research

Volumn 41, Issue 1, 2008, Pages 108-119

  Ojima, Iwao ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; CARBON NANOTUBE; DRUG CARRIER; FLUORESCENT DYE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; TAXOID;

ANIMAL; ARTICLE; CHEMISTRY; DRUG DESIGN; HUMAN; NEOPLASM;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOTIN; DRUG CARRIERS; DRUG DESIGN; FLUORESCENT DYES; HUMANS; IMMUNOTOXINS; NANOTUBES, CARBON; NEOPLASMS; TAXOIDS;

EID: 38949129079     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar700093f     Document Type: Article

References (42)

1. Jaracz, S.; Chen, J.; Kuznetsova, L. V.; Ojima, I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005, 13, 5043-5054.
2. Chen, J.; Jaracz, S.; Zhao, X.; Chen, S.; Ojima, I. Antibody-based toxin conjugates for cancer therapy. Exp. Opin. Drug Delivery 2005, 2, 873-890.
3. Wu, X.; Ojima, I. Tumor specific novel taxoid-monoclonal antibody conjugates. Curr. Med. Chem. 2004, 11, 429-438.
4. Ojima, I.; Geng, X.; Wu, X.; Qu, C.; Borella, C. P.; Xie, H.; Wilhelm, S. D.; Leece, B. A.; Bartle, L. M.; Goldmacher, V. S.; Chari, R. V. J. Tumor-specific novel taxoid-monoclonal antibody conjugates. J. Med. Chem. 2002, 45, 5620-5623.
5. Hamaan, P. R.; Hinman, L. M.; Hollander, I.; Beyer, C. F.; Lindh, D.; Holcomb, R.; Hallett, W.; Tsou, H.-H.; Upeslacis, J.; Shochat, D.; Mountain, A.; Flowers, D. A.; Bernstein, I. Gemtuzumab Ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 2002, 13, 47-58.
6. Chari, R. V. J. Targeted delivery of chemotherapeutics: Tumor activated prodrug (TAP) therapy. Adv. Drug Delivery Rev. 1998, 31, 89-104.
7. Bradley, M. O.; Webb, N. L.; Anthony, F. H.; Devanesan, P.; Witman, P. A.; Hemamalini, S.; Chander, M. C.; Baker, S. D.; He, L.; Horowitz, S. B.; Swindell, C. S. Tumor targeting by covalent conjugation of a natural fatty acid to taxol. Clin. Cancer Res. 2001, 7, 3229-3238.
8. Kuznetsova, L. V.; Chen, J.; Sun, L.; Wu, X.; Pepe, A.; Veith, J. M.; Pera, P.; Bernacki, R. J.; Ojima, I. Syntheses and evaluation of novel fatty acid-2nd-generation taxoid conjugates as promising anticancer agents. Bioorg. Med. Chem. Lett. 2006, 16, 974-977.
9. Leamon, C. P.; Reddy, J. A. Folate-targeted chemotherapy. Adv. Drug Delivery Rev. 2004, 56, 1127-1141.
10. Lu, Y.; Low, P. S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Delivery Rev. 2002, 54, 675-693.
11. Chu, T. C.; Marks, J. W., III; Lavery, L. A.; Faulkner, S.; Rosenblum, M. G.; Ellington, A. D.; Levy, M. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006, 66, 5989-5992.
12. Nagy, A.; Schally, A. V.; Halmos, G.; Armatis, P.; Cai, R.-Z.; Csernus, V.; Kovacs, M.; Koppan, M.; Szepeshazi, K.; Kahan, Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 1794-1799.
13. Luo, Y.; Bernshaw, N. J.; Lu, Z.-R.; Kopecek, J.; Prestwich, G. D. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm. Res. 2002, 19, 396-402.
14. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277, 665-667.
15. Vredenburg, M. R.; Ojima, I.; Veith, J.; Pera, P.; Kee, K.; Cabral, F.; Sharma, A.; Kanter, P.; Bernacki, R. J. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J. Natl. Cancer Inst. 2001, 93, 1234-1245.
16. Ojima, I.; Slater, J. C.; Michaud, E.; Kuduk, S. D.; Bounaud, P.-Y.; Vrignaud, P.; Bissery, M.-C.; Veith, J.; Pera, P.; Bernacki, R. J. Syntheses and structure-activity relationships of the second generation antitumor taxoids. Exceptional activity against drug-resistant cancer cells. J. Med. Chem. 1996, 39, 3889-3896.
17. Ojima, I.; Slater, J. S.; Kuduk, S. D.; Takeuchi, C. S.; Gimi, R. H.; Sun, C.-M.; Park, Y. H.; Pera, P.; Veith, J. M.; Bernacki, R. J. Syntheses and structure-activity relationships of taxoids derived from 14β-hydroxy-10- deacetylbaccatin III. J. Med. Chem. 1997, 40, 267-278.
18. Ojima, I.; Wang, T.; Miller, M. L.; Lin, S.; Borella, C.; Geng, X.; Pera, P.; Bernacki, R. J. Syntheses and structure-activity relationships of new second-generation taxoids. Bioorg. Med. Chem. Lett. 1999, 9, 3423-3428.
19. Ojima, I.; Lin, S.; Wang, T. The recent advances in the medicinal chemistry of taxoids with novel β-amino acid side chains. In The Chemistry and Biology of β-Amino Acids. Curr Med. Chem. 1999, 6, 927-954.
20. Geney, R.; Chen, J.; Ojima, I. Recent advance in the new generation taxane anticancer agents. Med. Chem. 2005, 1, 125-139.
21. Heird, W. C.; Lapillonne, A. The role of essential fatty acids in development. Annu. Rev. Nutr. 2005, 25, 549-571.
22. Hardman, W. E. Omega-3 fatty acids to augment cancer therapy. J. Nutr. 2002, 132, 3508S-3512S.
23. Wigmore, S. J.; Ross, J. A.; Falconer, J. S.; Plester, C. E.; Tisdale, M. J.; Carter, D. C.; Fearon, K. C. H. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996, 12, S27-S30.
24. Hawkins, R. A.; Sangster, K.; Arends, M. J. Apoptotic death of pancreatic cancer cells induced by polyunsaturated fatty acids varies with double bond number and involves an oxidative mechanism. J. Pathol. 1998, 185, 61-70.
25. Sauer, L. A.; Dauchy, R. T.; Blask, D. E. Mechanism for the antitumor and anticachectic effects of n-3 fatty acids. Cancer Res. 2000, 60, 5289-5295.
26. 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ. Brit. J. Cancer 1992, 66, 297-303.
27. Grammatikos, S. I.; Subbaiah, P. V.; Victor, T. A.; Miller, W. M. n-3 and n-6 fatty acid processing and growth effects in neoplastic and non-cancerous human mammary epithelial cell lines. Brit. J. Cancer 1994, 70, 219-227.
28. Diomede, L.; Colotta, F.; Piovani, B.; Re, F.; Modest, E. J.; Salmona, M. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int. J. Cancer Res. 1993, 53, 124-130.
29. Ernstoff, M. S. Phase III study of taxoprexin injection vs dacarbazine in patients with metastatic malignant melanoma. Norris Cotton Cancer Center, 2003, http://www.cancer.dartmouth.edu/clinicaltrials/trials/F0239.shtml.
30. Sunada, H.; Magun, B. E.; Mendelsohn, J.; MacLeod, C. L. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 3825-3829.
31. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res. 1992, 52, 121-126.
32. Liu, C.; Tadayoni, B. M.; Bourret, L. A.; Mattocks, K. M.; Derr, S. M.; Widdison, W. C.; Kedersha, N. L.; Ariniello, P. D.; Goldmacher, V. S.; Lambert, J. M.; Blättler, W.; Chari, R. V. J. Eradication of large colon tumor xenografts by trageted delivery of maytansinoids. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8618-8623.
33. Saleh, M. N.; LoBuglio, A. F.; Trail, P. A. Monoclonal antibody-based immunoconjugate therapy of cancer: Studies with BR96-doxorubicin. Basic Clin. Oncol. 1998, 15, 397-416.
34. Guillemard, V.; Saragovi, H. U. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res. 2001, 61, 694-699.
35. Jaime, J.; Page, M. Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro. Anticancer Res. 2001, 21, 1119-1128.
36. Chari, R. V. J.; Jackel, K. A.; Bourret, L. A.; Derr, S. M.; Tadayoni, B. M.; Mattocks, K. M.; Shah, S. A.; Liu, C.; Blätller, W.; Goldmacher, V. S. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 1995, 55, 4079-4084.
37. Kigawa, J.; Minagawa, Y.; Kanamori, Y.; Itamochi, H.; Cheng, X.; Okada, M.; Oishi, T.; Terakawa, N. Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 1998, 82, 697-702.
38. Ojima, I.; Habus, I.; Zhao, M.; Zucco, M.; Park, Y. H.; Sun, C.-M.; Brigaud, T. New and efficient approaches to the semisynthesis of taxol and its C-13 side chain analogs by means of β-lactam synthon method. Tetrahedron 1992, 48, 6985-7012.
39. Ojima, I. Use of fluorine in the medicinal chemistry and chemical biology of bioactive compounds - A case study on fluorinated taxane anticancer agents. Chem. Biol. Chem. 2004, 5, 628-635.
40. Reddy, J. A.; Westrick, E.; Vlahov, I.; Howard, S. J.; Santhapuram, H. K.; Leamon, C. P. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother. Pharmacol. 2006, 58, 229-236.
41. Leamon, C. P.; Reddy, J. A.; Vlahov, I. R.; Vetzel, M.; Parker, N.; Nicoson, J. S.; Xu, L.-C.; Westrick, E. Synthesis and biological evaluation of EC72: A new folate-targeted chemotherapeutic. Bioconjugate Chem. 2005, 15, 803-811.
42. Russell-Jones, G.; McTavish, K.; McEwan, J.; Rice, J.; Nowotnik, D. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J. Inorg. Biochem. 2004, 98, 1625-1633.